For the 10th consecutive year, the Blood and Marrow Transplant Program at the Northside Hospital Cancer Institute has been recognized as having among the best survival outcomes in the country for bone marrow transplants.
According to a company news release, the new Be The Match data show Northside among the top 20% of U.S. transplant programs in terms of volume of allogeneic transplants performed. The BMT program’s one-year survival of transplant patients was 79.4%.
BMT program director H. Kent Holland gives credit to Northside’s physicians and staff. “We have a very experienced team that spearheads the amazing work that takes place in our inpatient and outpatient BMT units, our stem-cell laboratory and blood donor center,” he said in a statement.
The NHCI also recently announced it is expanding treatment for acute lymphoid leukemia and certain types of non-Hodgkins lymphoma.
The nationally recognized for leukemia treatment and stem cell transplantation also offers Yescarta CAR T-cell therapy for patients with non-Hodgkins lymphoma and multiple myeloma and participates in immunotherapy trials for patients with acute myeloid leukemia as well as other “hematologic malignancies.”
Support real journalism. Support local journalism. Subscribe to The Atlanta Journal-Constitution today. See offers.
Your subscription to the Atlanta Journal-Constitution funds in-depth reporting and investigations that keep you informed. Thank you for supporting real journalism.